Abstract
Paediatric migraine headache is a common condition for which there is no general consensus on the choice of prophylactic. Riboflavin has been considered as a potential prophylactic which is well tolerated. This review examines the current literature regarding the efficacy of riboflavin as a prophylactic. There have been mixed results from both retrospective studies as well as randomised controlled trials. Whilst the adverse effect profile is minimal compared to other migraine prophylactics, further well-designed studies with larger sample sizes and longer follow-up are required.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
